CLSD · As filed with the SEC
Clearside Biomedical balance sheet, by fiscal year
The statement as Clearside Biomedical presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Balance Sheets · USD
| USD | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | FY2021 Dec 31, 2021 |
|---|---|---|---|---|
| Assets | ||||
| Current assets: | ||||
| Cash and cash equivalents | 20,020,000 | 28,920,000 | 48,258,000 | 30,436,000 |
| Accounts receivable | 507,000 | 170,000 | 0 | 10,000,000 |
| Prepaid expenses | 734,000 | 722,000 | 704,000 | 921,000 |
| Other current assets | 13,000 | 311,000 | 439,000 | 779,000 |
| Total current assets | 21,274,000 | 30,123,000 | 49,401,000 | 42,136,000 |
| Property and equipment, net | 3,225,000 | 2,996,000 | 755,000 | 238,000 |
| Operating lease right-of-use asset | 597,000 | 869,000 | 1,117,000 | 369,000 |
| Restricted cash and other assets | — | — | 30,000 | 160,000 |
| Other assets | 30,000 | 30,000 | — | — |
| Total assets | 25,126,000 | 34,018,000 | 51,303,000 | 42,903,000 |
| Liabilities and stockholders' deficit | ||||
| Current liabilities: | ||||
| Accounts payable (includes $491 and $331 to a related party as of December 31, 2024 and 2023, respectively) | 1,452,000 | 2,205,000 | 1,050,000 | 941,000 |
| Accrued liabilities (includes $304 and $215 to a related party as of December 31, 2024 and 2023, respectively) | 2,967,000 | 4,169,000 | 4,179,000 | 3,312,000 |
| Current portion of operating lease liabilities | 375,000 | 364,000 | 349,000 | 387,000 |
| Deferred revenue | 0 | 75,000 | 205,000 | — |
| Total current liabilities | 4,794,000 | 6,813,000 | 5,783,000 | 4,640,000 |
| Liability related to the sales of future royalties, net | 51,767,000 | 41,988,000 | 33,977,000 | — |
| Warrant liabilities | 6,692,000 | — | — | — |
| Operating lease liabilities | 328,000 | 649,000 | 936,000 | 288,000 |
| Other non-current liabilities | 400,000 | 480,000 | — | — |
| Total liabilities | 63,981,000 | 49,930,000 | 40,696,000 | 4,928,000 |
| Stockholders' deficit: | ||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized and no shares issued at December 31, 2024 and 2023 | 0 | 0 | 0 | — |
| Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2024 and 2023; 76,578,383 and 62,850,841 shares issued and outstanding at December 31, 2024 and 2023, respectively | 77,000 | 63,000 | 61,000 | 60,000 |
| Additional paid-in capital | 316,343,000 | 304,948,000 | 298,984,000 | 293,406,000 |
| Accumulated deficit | (355,275,000) | (320,923,000) | (288,438,000) | (255,491,000) |
| Total stockholders' deficit | (38,855,000) | (15,912,000) | 10,607,000 | 37,975,000 |
| Total liabilities and stockholders' deficit | 25,126,000 | 34,018,000 | 51,303,000 | 42,903,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.